Blepharospasm and hemifacial spasm: Long-term treatment with botulinum toxin;Blefarospasmo y espasmo hemifacial: Tratamiento a largo plazo con toxina botulínica

Neurologia

Volumn 28, Issue 3, 2013, Pages 131-136

  Gil Polo, C ^a   Rodriguez Sanz M F ^a   Berrocal Izquierdo, N ^a   Castrillo Sanz, A ^a   Gutierrez Rios R ^a   Zamora Garcia M I ^a   Mendoza Rodriguez A ^a   Duarte Garcia Luis J ^a  

^a Hospital Complejo Asistencial de Segovia   (Spain)

Author keywords

Blepharospasm; Botulinum toxin; Cranial dystonia; Eyelid dystonia; Hemifacial spasm; Post paralytic synkinesia

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE INCREASE; HEMIFACIAL SPASM; HUMAN; LONG TERM CARE; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PTOSIS;

BLEPHAROSPASM; BOTULINUM TOXINS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMIFACIAL SPASM; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875808492     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2012.03.009     Document Type: Article

References (26)

1. Bartolomé F.M., Fanjul S., Cantarero S., Hernández J., García Ruiz P.J. Distonías focales primarias: estudio descriptivo de 205 pacientes. Neurologia 2003, 18:59-65.
2. Duarte J., Mendoza A., García M.T. Epidemiología de la distonía primaria. Rev Neurol 1999, 29:884-886.
3. Singer C. Indicaciones manejo de la toxina botulínica. Rev Neurol 1999, 29:157-162.
4. Kenney C., Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008, 115:585-591.
5. Jankovic J., Schwartz K., Donovan D.T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990, 53:633-639.
6. Kraft S.P., Lang A.E. Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. CMAJ 1988, 139:837-844.
7. Costa J., Espírito-Santo C., Borges A., Ferreira J.J., Coelho M., Moore P., et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 2005, CD004900 Jan 25.
8. Costa J., Espírito-Santo C., Borges A., Ferreira J.J., Coelho M., Moore P., et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 2005, CD004899 Jan 25.
9. Smith A.G. Pearls and pitfalls in the therapeutic use of botulinum toxin. Semin Neurol 2004, 24:165-174.
10. Snir M., Weinberger D., Bourla D., Kristal-Shalit O., Dotan G., Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 2003, 136:99-105.
11. Cillino S., Raimondi G., Guépratte N., Damiani S., Cillino M., Di Pace F., et al. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye 2010, 24:600-607.
12. Mejia N.I., Vuong K.D., Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20:592-597.
13. Pérez-Saldaña M.T., Parkhutik V., Boscá-Blasco M.E., Claramonte B., Burguera-Hernández J.A. Espasmo hemifacial: más de 10 años de tratamiento con toxina botulínica. Rev Neurol 2007, 45:582-586.
14. Jitpimolmard S., Tiamkao S., Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998, 64:751-757.
15. Defazio G., Abbruzzese G., Girlanda P., Vacca L., Currà A., De Salvia R., et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002, 59:418-420.
16. Barbosa E.R., Takada L.T., Gonçalves L.R., Costa R.M., Silveira-Moriyama L., Chien H.F. Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience. Arq Neuropsiquiatr 2010, 68:502-505.
17. Echeverría Urabayen A., Fanjul S., Meseguer E., García Ruiz Espiga P.J. Evolución de la dosis de toxina botulínica tipo A en distonías craneocervicales Estudio comparativo a lo largo de ocho años. Rev Neurol 2004, 38:511-513.
18. Mauriello J.A., Dhillon S., Leone T., Pakeman B., Mostafavi R., Yepez M.C. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 1996, 80:1073-1076.
19. Gill H.S., Kraft S.P. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci 2010, 37:631-636.
20. García-Torres M.A., García-Ruiz Espiga P.J. Evolución a largo plazo de la dosis de toxina botulínica en el tratamiento del espasmo hemifacial. Rev Neurol 2004, 39:599.
21. Kollewe K., Mohammadi B., Dengler R., Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm 2010, 117:759-763.
22. Thussu A., Barman C.R., Prabhakar S. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation. Neurol India 1999, 47:206-209.
23. Taylor J.D., Kraft S.P., Kazdan M.S., Flanders M., Cadera W., Orton R.B. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 1991, 26:133-138.
24. Park Y.C., Lim J.K., Lee D.K., Yi S.D., Botulinum A toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993, 8:334-340.
25. Cakmur R., Ozturk V., Uzunel F., Donmez B., Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002, 249:64-68.
26. Aramideh M., Ongerboer de Visser B.W., Brans J.W., Koelman J.H., Speelman J.D. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry 1995, 59:309-311.